SMUG1 and neoplasm: Under a hypothesis that enzyme inhibition recapitulates enzyme knockdown and activation overexpression, one may expect a possible utility for SMUG1 activators or inhibitors in adjuvant settings, e.g. to sensitize HRD tumour to PARPi or ATRi, respectively [85, 90–92].